Melanotan II (10 mg) & PT-141 (10 mg) (Stack)
PT-141 (bremelanotide) and Melanotan II are melanocortin receptor agonists. PT-141 is used on-demand for sexual function, while Melanotan II acts on skin pigmentation and sexual function with daily dosing.
Reviewed by the AllPeptides.eu Editorial Team·Last reviewed: 2026-06-16
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
⚠️ For informational/educational purposes only. Not medical advice. We do not sell any products. Self-treatment carries serious risks — consult a healthcare professional. Disclaimer
How It Works
PT-141 and MT-II are cyclic peptide analogues that act on melanocortin receptors MC3R/MC4R in the CNS. PT-141 (a metabolite of MT-II) is FDA-approved for HSDD. MT-II retains activity in skin pigmentation (melanogenesis) and sexual function.
Quick Start
- Reconstitution of each vial: Add 3.0 mL BAC water → ~3.33 mg/mL.
- PT-141: 750–1750 mcg on-demand (≥45 minutes before); max. 1 dose/24h, ≤8/month.
- Melanotan II: 250–1000 mcg 1×/day with gradual titration.
- Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C, use within ~1 week.
PT-141 (On-Demand) & Melanotan II (Daily) Dosing
Route: Subcutaneously | Frequency: PT-141: on-demand | MT-II: 1×/day
| Week | Dose | Units (per injection) |
|---|---|---|
| PT-141: Initial | 500–750 mcg | 15–22 units (0.15–0.22 mL) |
| PT-141: Standard | 1000–1500 mcg | 30–45 units (0.30–0.45 mL) |
| PT-141: Full (FDA) | 1750 mcg | 52 units (0.52 mL) |
| MT-II: Wk. 1 | 250 mcg/day | 7.5 units (0.075 mL) |
| MT-II: Wk. 2 | 500 mcg/day | 15 units (0.15 mL) |
| MT-II: Wk. 3–4 | 750 mcg/day | 22 units (0.22 mL) |
| MT-II: Wk. 5+ (Loading) | 1000 mcg/day | 30 units (0.30 mL) |
| MT-II: Maintenance | 500–1000 mcg (2–3×/wk) | 15–30 units |
PT-141: ≥45 minutes before; max. 8 doses/month. MT-II: starting at 250 mcg, increasing by 250 mcg every 5–7 days. Nausea/flushing are common initially.
Reconstitution Steps
- Withdraw 3.0 mL BAC water for each vial (PT-141 or MT-II).
- Slowly inject against the side of the vial; avoid foaming.
- Gently swirl until dissolved.
- Label with peptide name, date, concentration; refrigerate at 2–8 °C, protect from light.
- Use within ~1 week.
Protocol Overview
- PT-141: On-demand subcutaneous use for sexual function; 1750 mcg (FDA).
- MT-II: Daily loading injections (4–8 wks), then 2–3×/wk for maintenance.
- Storage: Lyophilized: −20 °C; reconstituted: 2–8 °C.
Dosing Protocol
- PT-141: 500–750 mcg initially; titrate to 1750 mcg. On-demand, max. 8×/month.
- MT-II: 250 mcg/day → increase by 250 mcg every 5–7 days → 1000 mcg → maintenance.
- Timing: PT-141 ≥45 minutes before; MT-II at a consistent time daily.
- Break between cycles: After the cycle, a washout period of 8–12 weeks is recommended. The MC receptors (MC1R/MC4R) need time to recover — this break prevents hyperpigmentation and tolerance to PT-141's effects.
Washout & Cycle Restart
When can I restart?
After the cycle, a washout period of 8–12 weeks is recommended. The MC receptors (MC1R/MC4R) need time to recover — this break prevents hyperpigmentation and tolerance to PT-141's effects.
Minimum wait period: 8 weeks
Storage Instructions
- Lyophilized: −20 °C in a dark/dry place.
- Reconstituted: 2–8 °C; use within ~1 week.
- Avoid freeze-thaw cycles.
Important Notes
- PT-141: Do not exceed 1 dose/24h or 8 doses/month.
- MT-II: UV exposure enhances pigmentation; use sun protection.
- Monitor moles/nevi for any changes.
Potential Benefits & Side Effects
Potential Benefits:
- PT-141: Increased sexual desire (clinical studies).
- MT-II: Skin pigmentation without UV + sexual function.
Potential Side Effects:
- PT-141: nausea (mainly initially), flushing, headache, transient ↑ BP.
- MT-II: nausea, flushing, fatigue, decreased appetite, darkening of moles.
⚠️ Serious Warnings & Long-Term Risks
The following warnings are based on published literature, FDA labels, and post-marketing surveillance. They do not constitute medical advice. Consult a healthcare professional.
Mole changes & melanoma
Reports of atypical mole development and melanoma in users. EMA/TGA rejected its use as unsafe. MC1R activation may mask early signs of melanoma.
📄 Br J Dermatol 2015; TGA Safety AdvisoryHypertension & cardiovascular events
Reports of transient hypertension and rare cardiovascular events in Melanotan II users.
📄 Clin Toxicol 2013Mole changes & melanoma risk
Afamelanotide (Melanotan I / Scenesse®) activates MC1R, increasing melanin. Reports of atypical moles and skin lesions. Regular dermatological monitoring is required — increased pigmentation may mask early melanoma signs.
📄 EMA EPAR — Scenesse®; Br J Dermatol 2015Nausea, flushing & injection site reactions
Common adverse effects: nausea (~20%), headache, flushing, local injection site reactions. Usually mild and transient.
📄 Scenesse® FDA Label 2019Transient hypertension
Bremelanotide causes transient blood pressure increase (systolic ~6mmHg). Contraindicated in uncontrolled hypertension.
📄 FDA Label — Vyleesi®References
- Bremelanotide (Vyleesi) FDA Prescribing Information — Dosage & Safety — Bremelanotide (Vyleesi): dosing & safety
View Source - Bremelanotide: Mechanism — NCBI Bookshelf (LiverTox) — Bremelanotide: mechanism
View Source - Bremelanotide for HSDD: Clinical Studies (PMC) — Bremelanotide for HSDD: clinical studies
View Source - Melanotan-II Phase I Clinical Study — Melanotan-II: Phase I study
View Source
Recommended Supplements
Maca Root Extract
Ashwagandha (KSM-66)
🧬 General Wellness
Multivitamin (High-Quality)
Magnesium Glycinate
Vitamin D3 + K2
Omega-3 Fish Oil (EPA/DHA)
Probiotics (Multi-Strain)
Electrolytes (Na, K, Mg)
Liver Support (NAC / Milk Thistle)
External Sources & Regulatory Status
Regulatory Approvals
Vyleesi® · HSDD (women) (2019)
FDA approved (Vyleesi®)
Educational information. Not medical advice, and no efficacy claim is implied. Regulatory approval is not a use recommendation by AllPeptides.eu.
Continue Your Research
Explore tools and guides related to this protocol.
Important Disclaimer
The content of this website is provided exclusively for informational and educational purposes within the context of research literature.
Read the full Disclaimer →